TG Therapeutics Inc TGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $47.94
- Day Range
- $47.27–48.93
- 52-Week Range
- $26.76–59.30
- Bid/Ask
- $48.10 / $48.97
- Shares Outstanding
- 153.07M
- Market Cap
- $7.46B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 17.79
- Price/Sales
- 9.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 2.39%
Company Profile
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 399
- Website
- https://www.tgtherapeutics.com
Valuation
|
Metric
|
TGTX
|
|---|---|
Price/Earnings (Normalized) | 17.79 |
Price/Book Value | 12.35 |
Price/Sales | 9.72 |
Price/Cash Flow | 40.10 |
Price/Earnings
TGTX
Financial Strength
|
Metric
|
TGTX
|
|---|---|
Quick Ratio | 3.55 |
Current Ratio | 4.27 |
Interest Coverage | 3.71 |
Quick Ratio
TGTX
Profitability
|
Metric
|
TGTX
|
|---|---|
Return on Assets (Normalized) | 43.03% |
Return on Equity (Normalized) | 94.31% |
Return on Invested Capital (Normalized) | 54.38% |
Return on Assets
TGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|N!$wJ@ | LOCK|#b!#y | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|b>%fZk | LOCK|R@n<P | $83B | |||
| argenx SE ADR
ARGX
| LOCK|Zzptd$ | LOCK|>& | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|j%k>%d@ | LOCK|gstQ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|c@mbN! | LOCK|ZC | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^Rf#%&% | LOCK|xzX#z | $31B | |||
| Moderna Inc
MRNA
| LOCK|S&F@?q | LOCK|d@ | $25B | |||
| Incyte Corp
INCY
| LOCK|@ZM?q@m | LOCK|Ygp | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|>SNwnqM | LOCK|$m | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#^YRB!S | LOCK|qP | $16B |
United States